Announcement & Notice - Disclosure - Investor Relations

Corporate Governance Stock Information Disclosure Financials Presentations and Events Analyst Coverage Notices-Replacement of Lost Share Certificates Subscribe to Updates

Home > Investor Relations > Disclosure

Disclosure

Listing Documents Financial Report/ESG information Announcement & Notice IR Journal

2022-12-08

VOLUNTARY ANNOUNCEMENT - RESULTS FROM PHASE I CLINICAL TRIAL OF PORUSTOBART (HBM4003) IN COMBINATION WITH TORIPALIMAB IN ADVANCED MELANOMA
2022-11-21

VOLUNTARY ANNOUNCEMENT - ENTERING INTO COLLABORATION AGREEMENT WITH DRAGONFLY THERAPEUTICS
2022-11-15

DISCLOSEABLE TRANSACTION - DISPOSAL OF ASSETS
2022-11-11

CHANGE IN CHIEF FINANCIAL OFFICER AND APPOINTMENT OF CHIEF BUSINESS OFFICER
2022-11-11

INSIDE INFORMATION - ENTERING INTO LICENSE AND COLLABORATION AGREEMENT WITH MODERNATX, INC.
2022-11-03

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
2022-10-20

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF FIRST PATIENT OF B7H4X4-1BB BISPECIFIC ANTIBODY (HBM7008) PHASE I TRIALS IN THE UNITED STATES
2022-10-10

CLOSING THE STUDY OF PHASE III CLINICAL TRIAL OF TANFANERCEPT (HBM9036)
2022-10-10

LICENSE AGREEMENT WITH CSPC NBP PHARMACEUTICAL CO. LTD. FOR BATOCLIMAB (HBM9161) AND CHANGE IN USE OF PROCEEDS
2022-10-07

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
2022-10-03

VOLUNTARY ANNOUNCEMENT COMPLETION OF FIRST DOSING OF LAST PATIENT WITH HBM4003 PHASE Ib/II TRIAL
2022-09-27

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF FIRST PATIENT OF ANTI-TSLP FULLY HUMAN MONOCLONAL ANTIBODY (HBM9378) IN ASTHMA PHASE I TRIAL IN CHINA
2022-09-06

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
2022-08-31

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022
2022-08-15

CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE
2022-08-15

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF LAST PATIENT WITH HBM4003 PHASE Ib TRIAL
2022-08-04

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
2022-08-02

DATE OF BOARD MEETING
2022-07-27

GRANT OF SHARE OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME AND GRANT OF SHARE AWARDS PURSUANT TO THE POST-IPO SHARE AWARD SCHEME
2022-07-07

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022

1 ···16 17 18 ···22